Home » Newsletters » BioWorld Science

BioWorld Science

March 5, 2021

View Archived Issues

Antidiarrheal drug fights AML

New phase I study evaluates iExosomes in metastatic pancreatic cancer with KrasG12D mutation

Oral islatravir studied in new phase III trials as PrEP for HIV

New CRL4 inhibitors show cytotoxicity tumors with low CUL4 expression

Copper chelator TDMQ-20 reverses impairments in Alzheimer's disease models

Positive phase I data support advancing FOR-6219 to phase II development in endometriosis

Dosing begins in phase I study of DNX-2440 in patients with resectable liver metastasis

Landos reports positive phase I data for NX-13

Bi-functionalized nanoparticles described by Vall d'Hebron Institut de Recerca and collaborators

Eli Lilly presents promising data from SURPASS-2 study of tirzepatide in type 2 diabetes

University of Virginia patents regulatory T cells armed with bispecific antibodies

Yangtze River Pharmaceutical, Shanghai Haiyan Pharmaceutical Technology describe mu-opioid agonists

New JAK-1/TYK2 inhibitors synthesized at the National Institute of Pharmaceutical R&D

Cough triggers and symptoms among patients treated in COUGH-1 and COUGH-2

New NTRK1 inhibitors discovered by Luoxin Pharmaceutical, Shandong Luoxin Pharmacy Group

CYH-33 demonstrates preliminary antitumor activity in PIK3CA-mutant tumors

[68Ga]NOTA-AE-105 PET/MRI useful for prostate cancer evaluation and reduces biopsy needs

Youhe reports partial remission in phase I study of YH-001 with teriprizumab in solid tumors

Apellis ends development of APL-9 for severe COVID-19

FDA approves Actemra for systemic sclerosis-associated interstitial lung disease

NIAID closes ACTIV-3 substudies of BRII-196, BRII-198 and VIR-7831

Novel mutation in the IRF2BPL gene tied to rare neurodevelopmental disorder

Imperial psychedelic microdosing study pushes the envelope on participant blinding

TurnSole initiates phase I/II study of TS-020 in hospitalized COVID-19 patients

NervGen receives FDA feedback on phase I plans with NVG-291

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...